Latrepirdine not effective in Huntington's disease

Latrepirdine not effective in huntington's disease
Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease, according to a study published online Oct. 29 in the Archives of Neurology.

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according to a study published online Oct. 29 in the Archives of Neurology.

Karl Kieburtz, M.D., M.P.H., and colleagues from the HORIZON Investigators of the Study Group and the European Huntington's Disease Network, conducted a six-month, randomized, double-blind study of latrepirdine, 20 mg three times daily, versus placebo in 403 patients with mild-to-moderate HD, across 64 research centers in Australia, Europe, and North America. The effect of latrepirdine on cognition and global function was assessed.

The researchers observed no significant difference between latrepirdine-treated patients and placebo-treated patients in the mean change in the Mini-Mental State Examination score (1.5- and 1.3-point improvement, respectively). There was also no significant difference in the distribution of the Clinician Interview-Based Impression of Change, plus carer interview between the groups (P = 0.84). There were no significant differences on secondary efficacy outcomes measures of behavior, daily function, motor function, and safety. There was a similar incidence of adverse events for latrepirdine- and placebo-treated patients.

"In patients with mild-to-moderate HD and , treatment with latrepirdine for six months was safe and well tolerated but did not improve cognition or global function relative to placebo," the authors write.

Several authors disclosed to pharmaceutical companies, including Medivation and Pfizer, both of which supported the study and manufacture latrepirdine.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Drug shows promise for Huntington's disease

date Feb 08, 2010

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of ...

Reach2HD, a Phase II study in Huntington's disease, launched

date Jun 07, 2012

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) ...

Donepezil found helpful in dementia with lewy bodies

date Jul 31, 2012

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to ...

Recommended for you

Making waves with groundbreaking brain research

date Jul 03, 2015

New research by Jason Gallivan and Randy Flanagan suggests that when deciding which of several possible actions to perform, the human brain plans multiple actions simultaneously prior to selecting one of ...

Long-term memories are maintained by prion-like proteins

date Jul 02, 2015

Research from Eric Kandel's lab at Columbia University Medical Center (CUMC) has uncovered further evidence of a system in the brain that persistently maintains memories for long periods of time. And paradoxically, ...

Water to understand the brain

date Jul 02, 2015

To observe the brain in action, scientists and physicians use imaging techniques, among which functional magnetic resonance imaging (fMRI) is the best known. These techniques are not based on direct observations ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.